Nona Biosciences

The moment is finally here! Join us at Booth #417 and then head over to the Town & Country Room D at 12:30 PM to discover our groundbreaking Novel Enzyme Cleavable Linker for the Development of Next-Gen ADCs against Solid Tumors. ? Whether you have just a brief moment to drop by or want to engage in deeper conversation, we're here to explore how we can help you advance your next ADC therapeutic. ? Looking forward to seeing you there! ? #ADC #antibodies #drugdevelopment #antibodydiscovery #HCAb #heavychainantibodies

TCRm antibodies represent a breakthrough in cancer immunotherapy, combining T-cell receptor specificity with antibody properties to target a wider range of intracellular antigens. Unlike traditional therapies, TCRm antibodies offer unique advantages: - ?????????????? ?????????????? ??????????????????: Recognize intracellular antigens presented by MHC molecules, expanding beyond surface targets. - ???????????? ????????????????: Achieve subnanomolar affinity, potentially enhancing therapeutic effectiveness. - ???????????????? ???????????????????? ???? ???????????? (??????): Enable tumor cell killing through ADCC, CDC, and specific peptide-MHC recognition. - ????????????????-???????? ????????????????????????: Offer a long half-life and stability for sustained action. - ???????????????? ????????????????????: Easier to manufacture than TCR-based therapies, ideal for large-scale applications. Nona Biosciences' TCRm antibodies are leading the way with innovative design and high specificity, holding strong promise for advancing cancer treatment.?? Learn more: https://lnkd.in/eT-_VkKp #TCRm #TCRmimic #antibodies #HCAb #CancerResearch #Immunotherapy #Biotech

Looking forward to PEGS Europe! If you’re working on Antibody drug development with specific interests of TCR Mimic Antibody / Single Domain Antibody applications in Immunotherapies, ?visit me at poster section ·??????A085?Single Domain CD3 Antibody Enables Next-Generation T Cell Engagers for Enhanced Immunotherapies ·??????B080 Discovery of T-Cell Receptor Mimic Antibody Derived T-Cell Engager I will be talking about how our Harbour mice platform leverage the antibody based immunotherapies developments Excited to share ideas and learn from everyone there. Hope to see you! https://lnkd.in/e6FvjGpE #FullyHumanAntibody #PEGSEurope #ImmunoTherapy #Nanobody #TCRMimicAntibody

?? Join Nona Biosciences at World ADC 2024! ?? ?? Booth #417 ??? Presentation: Wednesday, November 6th ? Time: 12:30 PM ?? Speaker: Musheng Bao, Vice President, Head of Biology Topic: Discovery and Preclinical Validation of a Novel Enzyme Cleavable Linker for Development of Next-Gen ADC Against Solid Tumors Summary: Tackling the challenges of poor drug penetration and high tumor heterogeneity in ADC and other biologics, Nona Bioscience has developed a groundbreaking linker technology. This innovative linker leverages a unique cleavage mechanism, utilizing an enzyme abundant in the tumor microenvironment (TME) of solid tumors. Paired with our proprietary payloads, it enables efficient, tumor-specific release, independent of internalization. Our preclinical data shows promising efficacy and safety improvements with this linker-payload system. Don’t miss this opportunity to learn about the next generation of targeted cancer therapies!

An overview of the ???????? ????????? by Nona Biosciences?? HCAb PLUS? is the world’s first fully human heavy chain-only antibody (HCAb) platform, clinically validated and experimentally proven, and enables breakthrough in therapeutic modalities. ?????? ????????????????: ?? HBICE? Technology — Unleashing bispecifics, multispecifics, immunocytokines, and other cutting-edge formats with enhanced structure, size reduction, and chain simplicity. ?? Breakthrough Therapeutic Modalities — Designed for powerful applications in ADCs, RDCs, PROTACs, and other areas demanding precision, efficiency, and adaptability. ?? Superior Performance in CAR Therapies — HCAbs from our HCAb Harbour Mice? deliver reduced immunogenicity, high solubility, tissue penetration, and conjugation benefits, ideal for advanced CAR-based cell therapies. ?? Pioneering mRNA Therapies & Targeted Delivery — The compact size and structural benefits of HCAbs enable next-level mRNA designs and LNP modifications, opening up new avenues in targeted treatments. Nona Biosciences is leading the way with highly stable, low-immunogenic, fully human HCAbs for breakthrough therapies. Explore the future of therapeutic innovation with HCAb PLUS?: https://lnkd.in/ecfYaq5u #antibodies #fullyhuman #fullyhumanantibodies #HCAb #heavychainonlyantibodies #heavychainantibodies #nextgentherapeutics #Therapeutics #NonaBiosciences #HCAbPLUS #BiotechInnovation #ImmuneTherapy #ADC #mRNAtherapey #CARTtherapy #CART

Happy Friday, Everyone! ?? Let’s kick off the weekend with a behind-the-scenes look at how Nona's fully human Harbour Mice HCAb technology was created?? Swipe through the carousel to see more! From llamas to mice—Dr. Frank Grosveld, the visionary behind this technology, was inspired by the potential of VHH antibodies and set out to create fully human HCAbs using a transgenic mouse model. Discover how our HCAb Plus platform supports the development of next-gen biotherapeutic modalities: Learn More: https://lnkd.in/ecfYaq5u #HappyFriday #HarbourMice #Comic #fullyhuman #fullyhumanantibody #antibodies #VHH #singledomainantibody #HCAb #biotech #innovation

?????? ?????? ???????????????? ???? ???????????????????? ???????????????????? (??????????) ?????????????????????? ???????? ?????? ???????????????????????????? ?????????? Bispecific antibodies are engineered to bind two different antigens simultaneously, enabling more precise therapeutic interventions. This unique mechanism allows for innovative treatments in fields like oncology and immunotherapy, offering new hope for difficult-to-treat conditions. ?? ?????? ?????? ???????????????????????????? ?????????? ???????????????????? ???? ?????? ???????? ?????????????????????? ??????????????? ?? Early risk identification: Developability assessment uncovers potential challenges such as stability, immunogenicity, and manufacturability issues early in the development process. ?? ?? Increased success rates: Identifying risks upfront reduces development failures, allowing only the most promising bsAb candidates to advance, boosting the chances of creating safe, effective therapies. ? Learn more: https://lnkd.in/eQ2uhNrD #BispecificAntibodies #DevelopabilityAssay #Biotech #Oncology #Immunotherapy #DrugDevelopment #Pharma #PrecisionMedicine #Biologics #InnovativeTherapies #HealthcareInnovation

Last day at the Festival of Biologics. What an incredible time! We've had the pleasure of connecting with brilliant researchers from around the globe and showcasing the impact of our fully human #HarbourMice platform. Special thanks to Dr. Jiyong Zhang for his insightful presentation on how our HCAb Harbour Mice technology is driving biotherapeutic development forward. We're excited for the future of biologics—fully human is the way! ?? #FestivalofBiologics #FOB #FOB2024 #FOB24 #AntibodyDiscovery #fullyhuman #fullyhumanantibodies #antibodies #antibody #Biotherapeutics #HCAb #heavychainonly #InnovationInScience #FutureOfMedicine #LifeSciences #Biotech

Day 1 at the Festival of Biologics! What an amazing start to the event! We’re excited to already connect with so many of you at Booth #736. If you haven't dropped by yet, there is still time to do it and learn about how our HCAb technology is shaping the future of biotherapeutic development. ?? And don't forget to join Dr. Jiyong Zhang, Nona’s Chief Business Officer, for an insightful session on the latest advancements in immunotherapy using our HCAb Harbour Mice? platform. ??? When: Tomorrow Oct 16 at 9:35 am You won’t want to miss this exciting talk! Let’s continue making breakthroughs together. #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE

The Festival of Biologics is just around the corner, taking place next week from October 15-17 in Basel! We’re thrilled to be a Diamond Sponsor this year, and you can find us at Booth #736. Don’t miss the opportunity to learn how our HCAb technology can transform your biotherapeutic development. Also, make sure to catch Dr. Jiyong Zhang, Nona’s Chief Business Officer, as he shares the latest innovations in immunotherapy using our HCAb platform. It’s a session you won’t want to miss! Learn more about our HCAb Harbour Mice? platform: https://lnkd.in/dfgdKMeH #FestivalofBiologics #FOB #FOB2024 #HCAb #antibodies #biotherapeutics #Biotech #fullyhuman #CART #ADC #multispecific #bispecific #immunotherapy #Tcellengager #TCE